Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates

Executive Summary

Teva is looking to tap into $6.5bn in US sales of Herceptin and Rituxan in a new deal for North American rights to two of Celltrion's pipeline biosimilars for $160m upfront.

You may also be interested in...



Teva/Celltrion's Truxima Is First Biosimilar Rituxan To Reach US Market

Truxima will launch in the US on 11 November for oncology indications at a 10% discount to the list price of Roche’s innovator Rituxan. The launch marks Teva's first biosimilar launch in the US.

Enthusiasm For US Biosimilars Wanes For Some, But Not Others

Three years after the first biosimilar launched in the US, the market has failed to deliver notable return on investments. Some players like Mylan are going public with frustrations over market barriers, while others, like Amgen, say they are encouraged by steady progress. Teva, however, is limiting its investment in biosimilars.

Enthusiasm For US Biosimilars Wanes For Some, But Not Others

Three years after the first biosimilar launched in the US, the market has failed to deliver notable return on investments. Some players like Mylan are going public with frustrations over market barriers, while others, like Amgen, say they are encouraged by steady progress. Teva, however, is limiting its investment in biosimilars.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel